Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zai Lab Ltd ADR
(NQ:
ZLAB
)
15.66
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
400
Open
15.66
Bid (Size)
15.60 (1)
Ask (Size)
16.19 (3)
Prev. Close
15.66
Today's Range
15.66 - 15.66
52wk Range
13.48 - 39.50
Shares Outstanding
956,637,360
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
April 15, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
April 11, 2024
From
Zai Lab Limited
Via
Business Wire
Performance
YTD
-39.91%
-39.91%
1 Month
-3.63%
-3.63%
3 Month
-31.91%
-31.91%
6 Month
-34.91%
-34.91%
1 Year
-54.92%
-54.92%
More News
Read More
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
April 02, 2024
From
Zai Lab Limited
Via
Business Wire
Recap: Zai Lab Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
April 01, 2024
Via
Benzinga
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
April 01, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Zai Lab Limited
Via
Business Wire
What Happened With Zai Lab Stock?
December 21, 2023
Via
Benzinga
Shhh! 7 Small-Cap Stocks That Can Double by 2025
March 20, 2024
Via
InvestorPlace
Stock Disconnect Triggers Investor Exodus From CStone Pharma
March 14, 2024
Via
Benzinga
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
March 13, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in March Investor Conference
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
February 27, 2024
From
Zai Lab Limited
Via
Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
February 09, 2024
Via
Benzinga
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
January 25, 2024
From
Zai Lab Limited
Via
Business Wire
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
January 22, 2024
Via
Benzinga
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
January 10, 2024
From
Zai Lab Limited
Via
Business Wire
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
December 21, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Zai Lab Announces Participation in January Investor Conference
December 19, 2023
From
Zai Lab Limited
Via
Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
December 13, 2023
From
Paratek Pharmaceuticals, Inc.
Via
GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
December 12, 2023
From
Zai Lab Limited
Via
Business Wire
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.